Literature DB >> 19851316

NFAT proteins: emerging roles in cancer progression.

Maria Mancini1, Alex Toker.   

Abstract

The roles of nuclear factor of activated T cells (NFAT) transcription factors have been extensively studied in the immune system. However, ubiquitous expression of NFAT isoforms in mammalian tissues has recently been observed, and a role for these transcription factors in human cancer is emerging. Various NFAT isoforms are functional in tumour cells and multiple compartments in the tumour microenvironment, including fibroblasts, endothelial cells and infiltrating immune cells. How do NFAT isoforms regulate the complex interplay between these compartments during carcinoma progression? The answers lie with the multiple functions attributed to NFATs, including cell growth, survival, invasion and angiogenesis. In addition to elucidating the complex role of NFATs in cancer, we face the challenge of targeting this pathway therapeutically.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19851316      PMCID: PMC2866640          DOI: 10.1038/nrc2735

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  104 in total

Review 1.  NFAT proteins: key regulators of T-cell development and function.

Authors:  Fernando Macian
Journal:  Nat Rev Immunol       Date:  2005-06       Impact factor: 53.106

2.  A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT.

Authors:  Yousang Gwack; Sonia Sharma; Julie Nardone; Bogdan Tanasa; Alina Iuga; Sonal Srikanth; Heidi Okamura; Diana Bolton; Stefan Feske; Patrick G Hogan; Anjana Rao
Journal:  Nature       Date:  2006-03-01       Impact factor: 49.962

Review 3.  Transcriptional regulation by calcium, calcineurin, and NFAT.

Authors:  Patrick G Hogan; Lin Chen; Julie Nardone; Anjana Rao
Journal:  Genes Dev       Date:  2003-09-15       Impact factor: 11.361

Review 4.  Mechanisms of action of cyclosporine.

Authors:  S Matsuda; S Koyasu
Journal:  Immunopharmacology       Date:  2000-05

5.  Risks of leukaemia and solid tumours in individuals with Down's syndrome.

Authors:  H Hasle; I H Clemmensen; M Mikkelsen
Journal:  Lancet       Date:  2000-01-15       Impact factor: 79.321

Review 6.  Signalling to transcription: store-operated Ca2+ entry and NFAT activation in lymphocytes.

Authors:  Yousang Gwack; Stefan Feske; Sonal Srikanth; Patrick G Hogan; Anjana Rao
Journal:  Cell Calcium       Date:  2007-06-18       Impact factor: 6.817

7.  Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo.

Authors:  Honglu Zhang; Xiaoyu Xu; Joanna Gajewiak; Ryoko Tsukahara; Yuko Fujiwara; Jianxiong Liu; James I Fells; Donna Perygin; Abby L Parrill; Gabor Tigyi; Glenn D Prestwich
Journal:  Cancer Res       Date:  2009-06-09       Impact factor: 12.701

8.  The integrin alpha6beta4 functions in carcinoma cell migration on laminin-1 by mediating the formation and stabilization of actin-containing motility structures.

Authors:  I Rabinovitz; A M Mercurio
Journal:  J Cell Biol       Date:  1997-12-29       Impact factor: 10.539

9.  Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma.

Authors:  Masatoshi Jinnin; Damian Medici; Lucy Park; Nisha Limaye; Yanqiu Liu; Elisa Boscolo; Joyce Bischoff; Miikka Vikkula; Eileen Boye; Bjorn R Olsen
Journal:  Nat Med       Date:  2008-10-19       Impact factor: 53.440

View more
  161 in total

1.  Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer.

Authors:  Sandra Baumgart; Elisabeth Glesel; Garima Singh; Nai-Ming Chen; Kristina Reutlinger; Jinsan Zhang; Daniel D Billadeau; Martin E Fernandez-Zapico; Thomas M Gress; Shiv K Singh; Volker Ellenrieder
Journal:  Gastroenterology       Date:  2011-11-10       Impact factor: 22.682

Review 2.  Long non-coding RNAs and cancer: a new frontier of translational research?

Authors:  R Spizzo; M I Almeida; A Colombatti; G A Calin
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

3.  GnRH regulation of Jun and Atf3 requires calcium, calcineurin, and NFAT.

Authors:  April K Binder; Jean C Grammer; Maria K Herndon; Julie D Stanton; John H Nilson
Journal:  Mol Endocrinol       Date:  2012-03-22

Review 4.  Primers on molecular pathways--the NFAT transcription pathway in pancreatic cancer.

Authors:  Alexander König; Martin E Fernandez-Zapico; Volker Ellenrieder
Journal:  Pancreatology       Date:  2010-08-19       Impact factor: 3.996

Review 5.  NFAT, immunity and cancer: a transcription factor comes of age.

Authors:  Martin R Müller; Anjana Rao
Journal:  Nat Rev Immunol       Date:  2010-08-20       Impact factor: 53.106

6.  Calcineurin/NFATc1 pathway contributes to cell proliferation in hepatocellular carcinoma.

Authors:  Shuhuai Wang; Xinmei Kang; Shouqiang Cao; Hui Cheng; Di Wang; Jingshu Geng
Journal:  Dig Dis Sci       Date:  2012-06-22       Impact factor: 3.199

7.  Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy.

Authors:  Wei Wang; Jiang-Jiang Qin; Sukesh Voruganti; Bhavitavya Nijampatnam; Sadanandan E Velu; Ke-He Ruan; Ming Hu; Jianwei Zhou; Ruiwen Zhang
Journal:  Cancer Res       Date:  2018-09-14       Impact factor: 12.701

8.  NFATc2 is an intrinsic regulator of melanoma dedifferentiation.

Authors:  V Perotti; P Baldassari; A Molla; C Vegetti; I Bersani; A Maurichi; M Santinami; A Anichini; R Mortarini
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

9.  Endorepellin affects angiogenesis by antagonizing diverse vascular endothelial growth factor receptor 2 (VEGFR2)-evoked signaling pathways: transcriptional repression of hypoxia-inducible factor 1α and VEGFA and concurrent inhibition of nuclear factor of activated T cell 1 (NFAT1) activation.

Authors:  Atul Goyal; Chiara Poluzzi; Chris D Willis; James Smythies; Adam Shellard; Thomas Neill; Renato V Iozzo
Journal:  J Biol Chem       Date:  2012-10-11       Impact factor: 5.157

10.  Pim-selective inhibitor DHPCC-9 reveals Pim kinases as potent stimulators of cancer cell migration and invasion.

Authors:  Niina M Santio; Riitta L Vahakoski; Eeva-Marja Rainio; Jouko A Sandholm; Sanna S Virtanen; Michelle Prudhomme; Fabrice Anizon; Pascale Moreau; Päivi J Koskinen
Journal:  Mol Cancer       Date:  2010-10-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.